Pfizer Inc. (NYSE:PFE) Shares Acquired by Octavia Wealth Advisors LLC

Octavia Wealth Advisors LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 16.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 25,784 shares of the biopharmaceutical company’s stock after acquiring an additional 3,625 shares during the period. Octavia Wealth Advisors LLC’s holdings in Pfizer were worth $653,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Mcdonald Partners LLC grew its stake in Pfizer by 9.9% during the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock worth $2,926,000 after buying an additional 9,963 shares during the last quarter. Bank of Jackson Hole Trust acquired a new position in shares of Pfizer in the 4th quarter valued at $264,000. Harvey Capital Management Inc. purchased a new stake in Pfizer in the 4th quarter valued at $544,000. ING Groep NV boosted its stake in Pfizer by 48.6% during the 4th quarter. ING Groep NV now owns 1,013,230 shares of the biopharmaceutical company’s stock worth $26,881,000 after purchasing an additional 331,403 shares during the period. Finally, WCM Investment Management LLC grew its position in Pfizer by 128.7% during the 4th quarter. WCM Investment Management LLC now owns 115,913 shares of the biopharmaceutical company’s stock worth $3,062,000 after purchasing an additional 65,238 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.0%

Pfizer stock opened at $23.36 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a fifty day moving average price of $22.95 and a two-hundred day moving average price of $25.00. The firm has a market cap of $132.81 billion, a price-to-earnings ratio of 16.57, a P/E/G ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same period in the prior year, the firm posted $0.82 EPS. Pfizer’s quarterly revenue was down 7.8% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.36%. Pfizer’s dividend payout ratio is 124.64%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on PFE shares. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group upped their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.